

ARTICLE

High Production of SPARC/osteonectin/BM-40 in Mouse Metastatic B16 Melanoma Cell Lines*

Yasumasa KATO,^{1,4} Francis FRANKENNE,¹ Agn s NO L,¹ Naoki SAKAI,² Yoji NAGASHIMA,³
Shinri KOSHIKA,⁴ Kaoru MIYAZAKI,⁵ Jean-Michel FOIDART¹

¹Laboratory of Tumor and Developmental Biology, University of Liege, Faculty of Medicine, Liege, Belgium;
Departments of ²Urology and ³Pathology, Yokohama City University School of Medicine, Yokohama, Japan;

⁴Department of Biochemistry, Kanagawa Dental College, Yokosuka, Japan; ⁵Division of Cell Biology,
Kihara Institute for Biological Research, Yokohama City University, Yokohama, Japan

Production of SPARC/osteonectin/BM-40 was determined in mouse B16 melanoma clones BL6 and F10 (high metastatic) and F1 (low metastatic). SPARC was produced greater amount in BL6 and F10 than in F1 cells, showing a good agreement with their metastatic potentials. Moreover, SPARC production was not influenced by culture pH, even in the acidic

Keywords: SPARC, osteonectin, BM-40, melanoma, metastasis

conditions (\approx pH 5.9). Although tumor tissues show often low pH due to excessive amount of acidic metabolites such as lactate, most studies have been done in neutral pH. High SPARC production in the acidic medium, therefore, is thought to be an important potential for tumor invasive behaviour. (Pathology Oncology Research Vol 6, No 1, 24–26, 2000)

Introduction

SPARC (secreted protein, acidic and rich in cysteine)/osteonectin/BM-40 is a secreted Ca²⁺-binding glycoprotein of 43 kDa.^{1–3} SPARC expression has been shown in some specific tumors such as breast,⁴ colorectal,⁵ esophageal⁶ cancers, melanoma,^{7,8} astrocytoma,⁹ meningioma,¹⁰ and hepatocellular carcinoma.¹¹ Ledda et al¹² reported that SPARC antisense RNA abrogates the tumorigenicity of human melanoma cells. Some reports have shown the relationship between SPARC and matrix metalloproteinase (MMP) secretions. For example, SPARC is co-expressed with stromelysin-3 in colorectal cancer,⁵ and induces production of collagenase, stromelysin and gelatinase B,^{13,14} and mediates pro-gelatinase A activation via

membrane type 1-MMP (MT1-MMP).¹⁵ In addition, it stimulates migration of human renal cell carcinoma¹⁶ and prostatic cancer.¹⁷ Thus, SPARC is thought to play a role of tumorigenesis and tumor progression.

We have previously reported that the expression of gelatinase B by high metastatic mouse B16 melanoma clones (F10 and BL6) is stimulated by acidic culture conditions.^{18,19} As Martinez-Zaguil n et al²⁰ pointed out, despite the acidity of tumors, most *in vitro* assays of tumor cell function are routinely performed at neutral-to-alkaline medium pH. We therefore evaluated SPARC production in B16 melanoma clones cultured with neutral or acidic medium, and compared with their metastatic potentials in this study.

Materials and Methods

Cell culture

B16 variants (high metastatic BL6 and F10 and low metastatic F1) were used in this study. They were maintained in DME/F12 (Gibco/BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Sera-Lab, Sussex, UK).

Received: July 30, 1999; accepted: Jan 10, 2000

Correspondence: Yasumasa KATO, Ph.D., Department of Biochemistry, Kanagawa Dental College, 82 Inaoka-cho, Yokosuka 238-8580, Japan. Tel: +81-(0)468-22-8840, Fax: +81-(0)468-22-8839, E-mail: yasumasa@kdcnet.ac.jp

*This work was supported by Public Trust Haraguchi Memorial Cancer Research Found, Japan.




Figure 1. SPARC production by mouse B16 melanoma cells in neutral culture conditions (pH 7.3). Samples (10 mg protein) were separated by 10% SDS-PAGE under non reducing (-2ME) or reducing (+2ME) conditions. Western blotting was performed using SPARC polyclonal antibody. Arrow heads, SPARC.




Figure 2. Production of gelatinase B and SPARC by mouse B16 melanoma cell lines in the acidic culture conditions (pH 5.9). Cells were maintained in serum-free DME/F12 with pH 5.9 and 7.3 for 3 days. Concentrated CM (10 mg protein) was subjected to zymography (a) and Western blotting (b). Arrow, gelatinase B activity; arrow heads, SPARC.

Preparation of conditioned medium (CM)

Sub-confluent cultures were maintained in serum-free DME/F12 with pH 5.9 or 7.3 for 3 days as described previously.¹⁸ In the case of BL6 cells, they were cultured in the serum-free media for 3 days in the presence or absence of 10^{-6} M BB-94 (British Biotech, Oxford, UK). CM was collected, concentrated by precipitation with ammonium sulfate at 80% saturation.

Zymography

Gelatinase B activity was measured by gelatin-zymography as reported previously.¹⁸ The proteins (10 μ g) in CM were electrophoresed on 10% polyacrylamide gels containing 0.1% gelatin as the substrate. SDS was removed from the gels by washing with 2.5% Triton X-100. Enzyme reaction was carried out by incubating in the presence of 10 mM CaCl_2 at 37°C for 20 h. The resultant gels were stained with Coomassie Brilliant Blue R-250.

Western blotting

Samples (10 μ g protein) were separated by 10% SDS-PAGE under non reducing or reducing conditions and transferred onto Immobilon-P membrane (Millipore, Bedford, MA, USA). SPARC polyclonal antibodies (kind gifts from Dr. L. Fisher and Prof. E.H. Sage) and peroxidase-conjugated anti-rabbit IgG (Dako, Copenhagen, Denmark) were used as first and second antibody, respectively. Peroxidase was revealed by the enhanced chemiluminescence assay. (Amersham, Buckinghamshire, UK).

Results and Discussion

SPARC proteins, secreted in neutral pH (7.3), were detected by Western blot as 3 bands (43-, 42-, 40-kDa) in the reducing conditions and 4 bands (40-, 36-, 35-, 30-kDa) in the non reducing conditions, respectively (Figure 1). SPARC proteins were detected highly in BL6 and F10, but faint in F1 cells. As previously reported elsewhere,¹⁸ the secretion of gelatinase B by F10 and BL6 cells was considerably stimulated by acidic culture medium (pH 5.9) (Figure 2a). Their SPARC production remained identical with an identical pattern at pH 5.9 and 7.3 (Figure 2b).

It has been reported that SPARC was degraded by several MMPs including gelatinase B.²¹ Our results, however, did not show any significant degradation of SPARC at acidic pH, that would have been expected from gelatinase B overexpression. Moreover, the addition of BB-94, a synthetic MMP inhibitor, to the cultures did not affect SPARC electrophoretic mobility, suggesting that the several electrophoretic mobilities of SPARC bands could not be the consequence of proteolysis by MMPs (Figure 2b). The fact

that activation of gelatinase B was not significantly caused by acidic culture conditions also might deny participated in MMPs for protein ladder of SPARC. The different bands of SPARC may correspond to different glycosylated forms rather than to different degradation products. As previous reports mentioned that SPARC induced MMP production or activation, we expected that increased gelatinase B production in acidic medium pH is caused by over expression of SPARC as an autocrine manner. However, the culture medium that was conditioned at pH 5.9 and then neutralized, and that is considered to be high SPARC content as shown in figure 2, did not change gelatinase B production in F10 cells,¹⁹ suggesting that production of SPARC and gelatinase B is regulated independently.

Rempel et al¹⁰ have found that invasive meningiomas produced excessive amount of SPARC independently of grade, and that the increased SPARC expression promoted glioblastoma *in vitro* invasion. SPARC also induced cell motility of renal cell carcinoma associated with type IV collagen.¹⁶ In addition, SPARC production was well correlated with metastatic ability of mouse B16 melanoma cells in this study. Taken together, SPARC action might be a most effective in tumor intravasation or extravasation in the tumor metastasis process. The high expression of SPARC and gelatinase B particularly at acidic pH conditions therefore may independently support the metastatic behaviour of melanoma cells.

Acknowledgement

We would like to thank Dr. Larry W Fisher (NIDR, NIH, USA) and Prof. E. Helen Sage (Dept. of Biological Structure, Univ. of Washington, USA) for providing SPARC polyclonal antibodies. We would like to thank Prof. Norbert E. Fusenig (Div. of Carcinogenesis and Differentiation, German Cancer Research Center, Germany) for helpful discussion.

References

1. Termine JD, Kleinman HK, Whitson SW et al: Osteonectin, a bone-specific protein linking mineral to collagen. *Cell* 26:99-105, 1981.
2. Mason IJ, Taylor A, Williams JG, et al: Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell 'culture shock' glycoprotein of Mr 43,000. *EMBO J* 5:1465-1472, 1986.
3. Mann K, Deutzmann R, Paulsson M, Timpl R: Solubilization of protein BM-40 from a basement membrane tumor with chelating agents and evidence for its identity with osteonectin and SPARC. *FEBS Lett* 218:167-172, 1987.
4. Bellahcene A, Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. *Am J Pathol* 146:95-100, 1995.
5. Porte H, Chastre E, Prevot S, et al: Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. *Int J Cancer* 64:70-75, 1995.
6. Porte H, Triboulet JP, Kotelevets L, et al: Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. *Clin Cancer Res* 4:1375-1382, 1998.
7. Ledda F, Bravo AI, Adris S, et al: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. *J Invest Dermatol* 108:210-214, 1997.
8. Massi D, Franchi A, Borgognoni L, et al: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. *Hum Pathol* 30:339-344, 1999.
9. Rempel SA, Golembieski WA, Ge S, et al: SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. *J Neuropathol Exp Neurol* 57:1112-1121, 1998.
10. Rempel SA, Ge S, Gutierrez JA: SPARC: a potential diagnostic marker of invasive meningiomas. *Clin Cancer Res* 5:237-241, 1999.
11. Le Bail B, Faouzi S, Boussarie L, et al: Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. *J Pathol* 189:46-52, 1999.
12. Ledda MF, Adris S, Bravo AI, et al: Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. *Nature Med* 3:171-176, 1997.
13. Tremble PM, Lane TF, Sage EH, Werb Z: SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. *J Cell Biol* 121:1433-1444, 1993.
14. Shankavaram UT, DeWitt DL, Funk SE, et al: Regulation of human monocyte matrix metalloproteinases by SPARC. *J Cell Physiol* 173:327-334, 1997.
15. Gilles C, Bassuk JA, Pulyaeva H, et al: SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. *Cancer Res* 58:5529-5536, 1998.
16. Kato Y, Sakai N, Baba M, et al: Stimulation of motility of human renal cell carcinoma by SPARC/osteonectin/BM-40 associated with type IV collagen. *Invasion Metastasis* 18:105-114, 1999.
17. Jacob K, Webber M, Benayahu D, Kleinman HK: Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. *Cancer Res* 59:4453-4457, 1999.
18. Kato Y, Nakayama Y, Umeda M, Miyazaki K: Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. *J Biol Chem* 267:11424-11430, 1992.
19. Kato Y, Ozono S, Shuin T, Miyazaki K: Slow induction of gelatinase B mRNA by acidic culture conditions in mouse metastatic melanoma cells. *Cell Biol Int* 20:375-377, 1996.
20. Martinez-Zaguilán R, Seflor EA, Seflor RE, et al: Acidic pH enhances the invasive behavior of human melanoma cells. *Clin Exp Metastasis* 14:176-186, 1996.
21. Sasaki T, Gohring W, Mann K, et al: Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. *J Biol Chem* 272:9237-9243, 1997.